anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
30 tennis players aged 12-18, who practice tennis for at least 6 hours a week and have been playing regularly for at least 1 year will be included in the study. The positive effect of oculo-motor exercises to be included in the pre-tennis warm-up program on stroke performance will be investigated. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight). Participants will be given a backhand and forehand stroke evaluation consisting of a total of 60 strokes, 30 forehand and 30 backhand. In the first evaluation, the participants will be asked to do their regular warm-up program. The area between the baseline line, service line and singles side line on the tennis court will be marked and two target areas will be created, one on the right and one on the left. Players will be asked to take one stroke parallel and one stroke diagonally, and they will be expected to hit the marked target areas. One week later there will be a second evaluation. In the second evaluation, oculo-motor exercises will be included in the participants' warm-up programs and the stroke evaluation will be repeated. The data obtained will be evaluated whether oculo-motor exercises have a positive effect on the forehand and backhand stroke rate.
The human gastrointestinal tract hosts a complex and dynamic community of microorganisms known as the gut microbiota, which play a pivotal role in numerous physiological processes, including digestion, metabolism, and immune function. Recent research has highlighted the significant impact of diet on the gut microbiota composition and functionality, and the consequential effects on host health. Concurrently, there is growing evidence linking the gut microbiota to inflammation, a key factor in many chronic diseases such as inflammatory bowel disease (IBD), obesity, diabetes, and cardiovascular diseases (CVDs). This review explores how dietary components influence the gut microbiota composition, how these microbial changes affect inflammatory pathways, and the therapeutic implications of modulating this axis for chronic inflammatory disease prevention and management. Beneficial dietary patterns, such as the Mediterranean diet (MD) and plant-based diets, promote a diverse and balanced gut microbiota composition, supporting anti-inflammatory pathways. Conversely, the Western diet (WD), high in saturated fats and refined sugars, is associated with dysbiosis and increased inflammation. With all the links between the three variables considered, this review attempts to offer a thorough examination of the triangle formed by inflammation, the gut microbiota, and food.
PURPOSE: Scoliosis surgery is becoming increasingly frequent. Rate of readmission is little discussed in the literature. It is an interesting data for the patient's information and for public authorities to calculate cost-effectiveness. Aim of the study was to evaluate rate and causes of short and long-term readmissions in patients > 45 years old operated on for a scoliosis primary cases, then to look for predictors of these readmissions.
METHODS: In this monocentric retrospective cohort study, over 45 years-old scoliosis primary cases operated on between 2015 and 2018 and with a minimum of 2 years follow-up were included. The number of readmissions and their causes were analyzed. Rehospitalized patients (RH) were then compared to non-rehospitalized patients (NRH). Risk factors were sought using a multivariate analysis by logistic regression.
RESULTS: 105 patients were included (90% female; 64 ± 8 years). 56% were readmitted at least once. Main cause of readmission as pseudarthrosis (70%). Among the RH patients, fifty-eight required at least one revision. We found no significant difference between RH and NRH, apart from the rate of immediate post-operative medical complications which was significantly higher in RH (17% (n = 11) vs. 4% (n = 2), p = 0.04). According to multivariate analysis, BMI and age were found as predictors of readmission of mechanical origin, and BMI for readmissions of septic origin.
CONCLUSION: The readmission rate after scoliosis surgery was 56%. The main cause was pseudarthrosis. Rehospitalized patients had more immediate post-operative medical complications. The elderly and overweight patients are more likely to be readmitted for mechanical or septic reasons.
This study will test how parts of sensory cortex relate to different aspects of touch sensation. Healthy male and female adults (ages 18-45) will be enrolled. We will use low frequency repetitive transcutaneous magnetic stimulation (rTMS) to temporarily reduce activation in parts of the sensory cortex and will examine the effect of this procedure on perception of touch stimuli. After screening, participants will undergo three testing sessions. Session 1 will involve questionnaires and anatomical and functional MRI scans (non-invasive brain imaging) that will be used for localizing the correct regions to stimulate with the rTMS. Sessions 2 and 3 will involve active and control rTMS and testing of gentle (non-painful) touch sensation.
Contains sodium metabisulfite [see Description (11)], a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. 

In postmarketing experience, anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported during and within one hour following administration of sincalide [see Adverse Reactions (6)].

Sincalide for Injection is contraindicated in patients with a history of hypersensitivity to sulfites. Due to the potential for anaphylaxis, appropriate medical support should be readily available when Sincalide for Injection is administered. If anaphylaxis or other hypersensitivity reactions occur, immediately discontinue the infusion and initiate appropriate medical treatment. Observe patients closely during and after the infusion. Do not reinitiate Sincalide for Injection in patients who have experienced symptoms of hypersensitivity [see Contraindications (4)].
The trial will be a prospective trial of a convenience sample of skeletally mature patients with radiographically-confirmed distal radius fractures that can be managed without ORIF. The study population will be defined as all adult patients (\>18 years) with stable, non-displaced distal radius fractures. All patients will be independent in activities of daily living. Patients will be screened as candidates for enrollment into the study and if the patient satisfies the inclusion/exclusion criteria, a clinical research coordinator or the study PI/coPI will explain all essential elements of the clinical trial. If the patient agrees to participate, the study coordinator or PI/coPI will obtain informed consent. The patient will still be followed clinically per the PI/coPI's standard of care.
INTRODUCTION: Proximal femur fractures are common among older individuals and pose challenges in achieving effective post-operative analgesia. Age-related co-morbidities limit the selection of analgesics in this population. This study aimed to compare the safety and effectiveness of transdermal buprenorphine (TDB) patch with traditional analgesics after fixation of an extracapsular fracture of the proximal femur.
METHODOLOGY: A prospective randomized controlled study was conducted over a 2-year period, involving 60 patients who underwent surgery for extra capsular intertrochanteric fracture fixation. The patients were randomly assigned to two groups by random envelope method. Group A received an intravenous formulation of paracetamol and tramadol for the initial 48 h, followed by an oral formulation. Group B received a transdermal buprenorphine (TDB) patch delivering 5 mcg/hour immediately after surgery, which continued for 2 weeks postoperatively. During the 14-day monitoring period, patients' pain scores were assessed using the Visual Analog Scale (VAS) at rest and during movement. The primary objective was to maintain a VAS score of 4 or lower. Rescue analgesics were administered if the VAS score reached 6. The secondary objectives included evaluating the quantity of rescue analgesics required and monitoring for any adverse effects or complications.
RESULTS: Pain scores at rest and during movement were significantly lower in Group B at all-time points (p-value 0.0006 - ≤ 0.0001), and the requirement for rescue analgesia was also significantly lower in this group. The administration of the TDB patch did not result in any significant adverse effects.
CONCLUSION: TDB patch is secure and offers better compliance and analgesia than other analgesics in the postoperative period whilst treating proximal femur extra capsular fracture.
PROBLEM TO BE SOLVED: To obtain the subject cleansing agent having excellent cleaning performance and use feeling such as excellent bubble removal during rinsing, free from of e.g. clamminess and causing no rough skin after its use by including hydroxyapatite and an amino acid-based surfactant. SOLUTION: This skin cleansing agent is obtained by including hydroxyapatite, pref., amorphous one, having a molar ratio Ca/P of 1.4-1.8, (B) 1-40 wt.% of an amino acid-based surfactant (e.g. N-acylglutamic acid salt), and pref. furthermore (C) 1-50 wt.% of a higher fatty acid salt (e.g. potassium laurate, potassium myristinate). The content of the component A is 0.05-5.0 wt.%, based on the total weight of the cleansing agent. The average particle diameter of the apatite powder is pref. 0.1-10.0 μm. This cleansing agent can also be compounded with e.g. an anionic surfactant, ethylene glycol.
Intellectual disability (ID), which affects around 2% to 3% of the population, accounts for 0.63% of the overall prevalence of neurodevelopmental disorders (NDD). ID is characterized by limitations in a person's intellectual and adaptive functioning, and is caused by pathogenic variants in more than 1000 genes. Here, we report a rare missense variant (c.350T>C; p.(Leu117Ser)) in HACE1 segregating with NDD syndrome with clinical features including ID, epilepsy, spasticity, global developmental delay, and psychomotor impairment in two siblings of a consanguineous Pakistani kindred. HACE1 encodes a HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1), which is involved in protein ubiquitination, localization, and cell division. HACE1 is also predicted to interact with several proteins that have been previously implicated in the ID phenotype in humans. The p.(Leu117Ser) variant replaces an evolutionarily conserved residue of HACE1 and is predicted to be deleterious by various in silico algorithms. Previously, eleven protein truncating variants of HACE1 have been reported in individuals with NDD. However, to our knowledge, p.(Leu117Ser) is the second missense variant in HACE1 found in an individual with NDD.
PURPOSE: A method for preparing an external use skin composition containing an Astragalus Membranaceus extract is provided to extract active ingredients from natural products. CONSTITUTION: An external use skin composition contains an Astragalus Membranaceus extract as an active ingredient. The extract is prepared using water. The active ingredients are amino acids, gamma-amino butyric acid, astragaloside IV, astragaloside(I, II), calycosin, formononetin, pinitol, lupenone, or beta-sitosterol. A method for preparing the active ingredient from Astragalus Membranaceus comprises: a step of inputting Astragalus Membranaceus into a subcritical extractor; a step of injecting water to the extractor and extracting active ingredients; and a step of collecting the active ingredients. [Reference numerals] (AA) Dielectric constant (-); (BB) Dielectric constant; (CC) Ionic product; (DD) Temperature(°C)
PURPOSE:To provide an antiarrythmic agent containing d-disopyramide or its acid addition salt as an active component and free from the side effect of hypoglycemia. CONSTITUTION:The objective antiarrhythmic agent contains d-disopyramide or its acid addition salt as an active component. The d-isomer of disopyramide has extremely low hypoglycemic activity compared with the l-isomer and has comparable cardiotropic activity. Accordingly, an antiarrhythmic agent which does not induce hypoglycemia can be produced by using the d-isomer free from the hypoglycemic side effect as the sole active component. The d-disopyramide used as the active component can be produced by crystallizing disopyramide from 1:10 mixture of methanol and acetone in the form of the salt with d- or l-tartaric acid. The optically resolved d-disopyramide can be used in the form of an acid addition salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, etc., or an organic acid such as citric acid.
Sepsis results when a severe infection overwhelms the normal regulatory mechanisms of the immune system, resulting in a dysregulated host response characterized by new-onset organ failure. A wide range of infectious challenges can induce sepsis, resulting in an even wider range of maladaptive immune responses. This makes sepsis a syndromic diagnosis without a unifying, underlying molecular mechanism. The next step toward personalized medicine for sepsis is to resolve the heterogeneity across the universe of septic patients in order to establish pathobiologically homogenous sepsis "endotypes" that have uniformly defined changes in physiology and immunology. Defining the mechanisms of immune dysfunction within these endotypes will provide a roadmap for the application of immunomodulatory therapies for sepsis. This approach can drive in a paradigm shift in sepsis treatment, moving beyond supportive care and toward active efforts to restore normal immune function.
NEW MATERIAL:A compound expressed by the formula (R and R<1> are CH3 or OH; R<2> is H or lower alkyl; the wavy line represents Z or E isomer). EXAMPLE:Methyl achimilate A. USE:A medicine having antitumor action. PREPARATION:The flower part of Achillea millefolium L. of the family Composite which a natural polyoxide having antitumor action is dried and extracted with a polar organic solvent, e.g. methanol, at room temperature for several days and the resultant extract is separated by shaking using a water-immiscible lower alcohol, e.g. butanol. An acidic substance is then extracted with a basic solution and an aqueous layer is acidified and extracted with an organic solvent, e.g. ethyl acetate. The resultant acidic substance is separated by silica gel chromatography to afford the aimed active substance corresponding to P388 (achimilic acid) expressed by the formula (R<2> is H), which is then esterified to give the compound expressed by the formula (where R<2> is alkyl).
The present invention discloses medicine for treating gastrosis and enteropathy and a preparing method thereof. The effective ingredient of the medicine is carbon powder which is obtained by that carbon frying is carried out to full animal skin with hair. The carbon powder is matched with pharmaceutically common auxiliary materials to prepare various oral dosage forms. A favorable formula of the medicine comprises 10 to 20 portions of carbon fried powder of full rabbit skin with hair, 30 to40 portions of carbon fried powder of full cow skin with hair, 30 to40 portions of carbon fried powder of full sheep skin with hair, 10 to20 portions of carbon fried powder of full dog skin with hair and 5 to10 portions of carbon fried powder of full donkey skin with hair. The present invention is mainly used for treating gastrosis and enteropathy such as chronic gastrorrhagia, stomach ulcers, duodenal ulcers, superficial gastritis, antral gastritis, partial or extensive atrophic gastritis, atrophic antral gastritis, hyperplastic gastritis, atrophic gastritis accompanied with intestinal metaplasia, prolapse of gastric mucosa, duodenal bulb inflammation, chronic enteritis, colonitis, etc. The present invention has the advantages of good therapeutic effect, slight toxic and side effect, good therapeutic effect for a middle and long term, low relapse rate, rapid effect, oral administration, convenient use and portability. One course of treatment includes 15 days.
All subjects giving written informed consent. In this multicenter, controlled, prospective cohort study, the outpatient and inpatient chronic insomnia patients' baseline demographic data were collected, including age, gender, education background, and medication history. Venous blood samples were collected and sent to laboratory test for blood routine, and blood biochemistry at Baseline and Week 4. The Pittsburgh sleep quality index (PSQI) was used to assess the patients' sleep quality at baseline and week 4. Objective sleep quality data is assessed by wearing a Sleep wearable devices. The classic Morningness-Eveningness Questionnaire and wearable devices was used to assess the patients' chronotype at baseline and week 4.Subjects who visit the TCM clinic of this project received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks. Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient. Subjects from TCM clinic who had previously taken Western medicine hypnotics continued taking them, and for those who had not taken before, Western medicine hypnotics shall not be given/prescribed. Subjects who visit the Western medicine clinic of this project received Estazolam 1mg tablet orally once daily for 4 weeks. The participants will have a follow-up visit every two weeks, and the prescription would be adjusted according to the condition of illness.Cessation rate of Western medicine hypnotics was assessed at Month 6.
Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
A determination for hospital admittance by a consulting psychiatrist will be made prior to study participation. Only those persons being admitted to the psychiatric ward will be eligible to enroll in this study. After consenting to participate in the trial and meeting inclusion criteria for this study (to include a baseline BDI, BSS, and BHS), voluntarily presenting acutely depressed patients, with or without suicidal ideation, will be randomized into two groups and administered standard of care treatment with intravenous ketamine (0.2mg/kg over 1-2 minutes) or standard of care treatment with intravenous normal saline (equal volume to ketamine dose). All prepared study solutions will be mixed and administered by ED staff and/or nursing staff as per the existing NMCSD ED protocols. All subjects will be blinded to the treatment given, either an IV bolus dose of ketamine at 0.2-mg/kg over 1-2 minutes or a placebo solution composed of an equal IV bolus dose (by overall volume) of 0.9 normal saline solution will be administered. Thereafter, all patients will be evaluated clinically with a BSS, BHS, and BDI at 40, 80, 120, and 240 minutes. All study participants will be monitored medically in the ED for at least the full 240-minute protocol and once declared medically clear, in accordance with standard of care practices by the ED providers, will be transferred to the inpatient psychiatric ward for further monitoring for at least 24-hours prior to discharge from the hospital. All enrolled patients will be administered another BSS, BHS, and BDI prior to discharge from the hospital. The length of hospital stay will also be recorded for further analysis, but will not be considered a secondary outcome measure for this study. Psychiatric determination for discharge from the hospital will be based on clinical assessment, presentation history, and hospital course and is not considered an outcome measure for this study. All patients included in this study will be re-assessed within 2 weeks with another BSS, BHS, and BDI for determination of sustainability of effects. Appropriate follow-up care with a psychiatrist will be afforded to all study participants after discharge from the hospital. Additionally, should any severe adverse side effects develop; the treatment administered to enrolled patients may be un-blinded by a third-party shift medical monitor (i.e. the Charge Nurse) on request from the emergency room provider. Additionally, given the potential psychotropic effects of ketamine and to assure that patients are sufficiently monitored and appropriately medically cleared, all participants in the study will be required to remain under clinical observation in the emergency room prior to transfer to the psychiatric ward for, at least, the full 4-hour treatment cycle or longer as clinically indicated. All participants in this study will only be allowed to enroll in this study and undergo this protocol's treatment once.
PURPOSE: To obtain a skin external medicine having both of sunburn preventing effect and injurious insect-repelling effect, and safe to skin and satisfying even also organoleptic properties by mixing both of a repelling component of a biting injurious insect and an ultraviolet light-scattering agent. CONSTITUTION: This skin external medicine contains a repelling component (e.g. N,N-diethyl-m-tolamide or dimethylphthalate) of a biting injurious insect and an ultraviolet light-scattering agent (e.g. titanium oxide or zirconium oxide). This skin external medicine is especially useful as a cosmetic for preventing of sunburn or a repelling agent of a biting injurious insect and is used in various shapes such as a fundamental cosmetic such as a latex, a cream and a beauty lotion or an aerosol product, etc. Preferably, a mixing amount of a repelling component for a biting injurious insect is 0.1-20wt.% and a mixing amount of an ultraviolet light-scattering agent is 0.1-90wt.%, especially 1-60wt.%.
Consenting volunteers of at least 18 years old with no morbidity, including males, and females who are not pregnant will be recruited for the study. A maximum of 28 volunteers may be enrolled with a reasonable sampling of ethnicities from the Nashville area, and an effort will be made to recruit equal numbers of males and females. Additionally, an effort will be made to study as old a population as possible and to recruit relatively similar age groups for males and females. All volunteers will be admitted to the Vanderbilt Clinical Research Center (CRC) as inpatients.

A complete health history and physical examination will be conducted by a physician. Volunteers will be asked to collect and bring their first morning voided urine for baseline urinalysis. An EKG, baseline blood analysis, vital signs, and questions about feelings and adverse events will be asked prior to supplement administration. All tests will be repeated at various intervals throughout the 24-hour study period. A physician will oversee all clinical aspects of the study and will be responsible for all trial-related medical decisions. Pharmacokinetics will be studied through the blood analyses at intervals throughout the study and 24-hour urine collection after administration of the supplement.